Nerinetide is under clinical development by NoNO and currently in Phase III for Acute Ischemic Stroke. According to GlobalData, Phase III drugs for Acute Ischemic Stroke have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nerinetide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nerinetide is under development for the treatment of acute ischemic stroke including strokes with endovascular intervention, procedurally-induced strokes, aneurysmal subarachnoid hemorrhage, traumatic brain injury and ischemic cerebral stroke, retinal ischemia, pain, epilepsy, Alzheimer’s disease and anxiety. The therapeutic candidate is administered through intravenous infusion. NA-1 (also known as Tat-NR2B9c) acts by targeting PSD-95 a postsynaptic scaffolding protein.
NoNO is a pharmaceutical company that provides research, development and commercialization of medicines for the treatment of neurological disorders. It develops therapeutic targets NA-1, lead therapeutic and a proprietary inhibitor of PSD-95 proteins. It also develops TRPM7 and inhibitors of Src-ND2 interactions. NoNO develops products for common health disorders with unmet needs, including stroke, traumatic brain injury, pain, and others. The company holds expertise in the development of a safe and effective treatment for acute neurological disorders, especially acute ischemic stroke, subarachnoid hemorrhage and procedurally induced strokes. NoNO is headquartered in Toronto, Ontario, Canada.
For a complete picture of Nerinetide’s drug-specific PTSR and LoA scores, buy the report here.